Calliditas Therapeutics provides business update ahead of conference

Calliditas Therapeutics provided a business update for the fourth quarter of 2023 and certain preliminary, unaudited key financial information for the fourth quarter and full year 2023, as follows: Q4 preliminary product revenue growth with net Tarpeyo revenues of $31M-$33M for the quarter, representing growth over Q3. Preliminary net Tarpeyo revenues of $100M-$102M for 2023, representing over 170% year over year growth compared to 2022. Preliminary total revenues reaching $110M-$113M for 2023, as a result of milestone payments and royalty income from the Nefecon franchise outside the U.S. Record quarter in terms of enrollments with 555 new Tarpeyo prescriptions in the fourth quarter. The information above reflects our preliminary estimates with respect to such results based on currently available information. We have provided ranges, rather than specific amounts, for the preliminary results described above primarily because our financial closing procedures are not yet complete and, as a result, our final results may vary from the preliminary estimates.